LUNG - Pulmonx Corp Stock Price, Fair Value and News

7.75USD-0.09 (-1.15%)Market Closed

Market Summary

USD7.75-0.09

Market Closed

-1.15%

LUNG Stock Price

View Fullscreen

LUNG RSI Chart

LUNG Valuation

Market Cap

300.8M

Price/Earnings (Trailing)

-5.12

Price/Sales (Trailing)

4.12

EV/EBITDA

-4.81

Price/Free Cashflow

-7.92

LUNG Price/Sales (Trailing)

LUNG Profitability

Operating Margin

100.00%

EBT Margin

-79.59%

Return on Equity

-53.15%

Return on Assets

-35.69%

Free Cashflow Yield

-12.63%

LUNG Fundamentals

LUNG Revenue

Revenue (TTM)

73.0M

Rev. Growth (Yr)

29.71%

Rev. Growth (Qtr)

-2.2%

LUNG Earnings

Earnings (TTM)

-58.7M

Earnings Growth (Yr)

13.31%

Earnings Growth (Qtr)

Breaking Down LUNG Revenue

Last 7 days

-2.1%

Last 30 days

26.2%

Last 90 days

6.5%

Trailing 12 Months

-40.1%

How does LUNG drawdown profile look like?

LUNG Financial Health

Current Ratio

6.95

Debt/Equity

0.29

Debt/Cashflow

-1.15

LUNG Investor Care

Shares Dilution (1Y)

2.83%

Diluted EPS (TTM)

-1.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	73.0M	0	0	0
2023	57.4M	60.7M	64.8M	68.7M
2022	50.0M	51.7M	51.9M	53.7M
2021	33.4M	41.9M	44.5M	48.4M
2020	35.4M	31.7M	33.3M	32.7M
2019	23.2M	26.3M	29.4M	32.6M
2018	0	0	0	20.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Pulmonx Corp

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.

CEO	Mr. Glendon E. French
WEBSITE	https://pulmonx.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	269

Pulmonx Corp Frequently Asked Questions

What is the ticker symbol for Pulmonx Corp? What does LUNG stand for in stocks?

LUNG is the stock ticker symbol of Pulmonx Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pulmonx Corp (LUNG)?

As of Fri Jul 26 2024, market cap of Pulmonx Corp is 300.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LUNG stock?

You can check LUNG's fair value in chart for subscribers.

Is Pulmonx Corp a good stock to buy?

The fair value guage provides a quick view whether LUNG is over valued or under valued. Whether Pulmonx Corp is cheap or expensive depends on the assumptions which impact Pulmonx Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LUNG.

What is Pulmonx Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, LUNG's PE ratio (Price to Earnings) is -5.12 and Price to Sales (PS) ratio is 4.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LUNG PE ratio will change depending on the future growth rate expectations of investors.